TRCT
IMNM icon

Tower Research Capital (TRC)’s Immunome IMNM Stock Holding History

Tower Research Capital (TRC)’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$145K Sell
6,847
-13,556
-66% -$290K ﹤0.01% 1926
2026
Q1 		$446K Buy
20,403
+19,446
+2,032% +$433K 0.01% 989
2025
Q4 		$20.6K Sell
957
-6,044
-86% -$106K ﹤0.01% 3080
2025
Q3 		$82K Buy
7,001
+63
+0.9% +$627 ﹤0.01% 2157
2025
Q2 		$64.5K Buy
6,938
+3,802
+121% +$31.2K ﹤0.01% 2748
2025
Q1 		$21.1K Sell
3,136
-5,472
-64% -$52.5K ﹤0.01% 2908
2024
Q4 		$91.4K Buy
8,608
+7,129
+482% +$86.1K ﹤0.01% 2189
2024
Q3 		$21.6K Sell
1,479
-523
-26% -$7.43K ﹤0.01% 3191
2024
Q2 		$24.2K Buy
2,002
+909
+83% +$14.2K ﹤0.01% 3651
2024
Q1 		$27K Buy
+1,093
New +$22.2K ﹤0.01% 2734
2023
Q3 		– Sell
-3,040
Closed -$24K – 6078
2023
Q2 		$24K Buy
3,040
+1,712
+129% +$9.36K ﹤0.01% 3220
2023
Q1 		$7K Sell
1,328
-1,030
-44% -$5.04K ﹤0.01% 4744
2022
Q4 		$5K Buy
+2,358
New +$9.5K ﹤0.01% 4873
2022
Q3 		– Sell
-2,489
Closed -$8K – 6261
2022
Q2 		$8K Buy
2,489
+2,357
+1,786% +$8.58K ﹤0.01% 4679
2022
Q1 		$1K Sell
132
-794
-86% -$5.94K ﹤0.01% 5807
2021
Q4 		$12K Buy
+926
New +$16.5K ﹤0.01% 4287
2021
Q3 		– Sell
-100
Closed -$2K – 5947
2021
Q2 		$2K Sell
100
-3,129
-97% -$69.1K ﹤0.01% 5047
2021
Q1 		$110K Sell
3,229
-1,841
-36% -$45.8K ﹤0.01% 2517
2020
Q4 		$49K Buy
+5,070
New +$59.1K ﹤0.01% 3142

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Tower Research Capital (TRC)'s IMNM Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Immunome (IMNM) stake by 66% in Q2 2026, selling an estimated $290K and leaving 6,847 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #1926.

Tower Research Capital (TRC) first reported a position in IMNM in Q4 2020 and has held it in 19 quarters since. The position peaked at $446K in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Tower Research Capital (TRC) held 6,847 shares of Immunome worth $145K as of Q2 2026.
  • Tower Research Capital (TRC) sold 13,556 Immunome shares in Q2 2026, an estimated $290K.
  • Immunome made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1926 holding.
  • Tower Research Capital (TRC) first reported a position in Immunome in Q4 2020 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Immunome position peaked at $446K in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.